Clinical Trials Logo
  1. Home
  2. Hyperlipidemia
  3. NCT00136942
  4. Details
NCT00136942 Clinical Trial

A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol

Hyperlipidemia Clinical Trial

— ACTFAST SWISS  

Official title:
A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00136942
Other study ID # A2581089
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 2005

Study information
Verified date February 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Recruitment information / eligibility
Status Completed
Enrollment 370
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening - LDL-C < 6.0 mmol/l - Triglyceride level < 5.0 mmol/l. Exclusion Criteria: - Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Atorvastatin

Locations
Country Name City State
Switzerland Pfizer Investigational Site Basel BS
Switzerland Pfizer Investigational Site Binningen BL
Switzerland Pfizer Investigational Site Duedingen FR
Switzerland Pfizer Investigational Site Ecublens VD
Switzerland Pfizer Investigational Site Geneve GE
Switzerland Pfizer Investigational Site Langenthal BE
Switzerland Pfizer Investigational Site Lausanne VD
Switzerland Pfizer Investigational Site Liestal BL
Switzerland Pfizer Investigational Site Lugano TI
Switzerland Pfizer Investigational Site Malvaglia TI
Switzerland Pfizer Investigational Site Melide TI
Switzerland Pfizer Investigational Site Onex GE
Switzerland Pfizer Investigational Site Pfaeffikon SZ
Switzerland Pfizer Investigational Site Prilly VD
Switzerland Pfizer Investigational Site Siebnen SZ
Switzerland Pfizer Investigational Site Thun BE
Switzerland Pfizer Investigational Site Unteraegeri ZG
Switzerland Pfizer Investigational Site Vezia TI
Switzerland Pfizer Investigational Site Zuerich ZH
Switzerland Pfizer Investigational Site Zug ZG

Sponsors (1)
Lead Sponsor Collaborator
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Country where clinical trial is conducted

Switzerland, 

Outcome
Type Measure Description Time frame Safety issue
Primary The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
Secondary The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.
See also
  Status Clinical Trial Phase
Completed NCT00001154 - Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
Completed NCT02927184 - Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease Phase 2
Completed NCT04640012 - Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics of DC371739 Single-Dose Treatment in Healthy Subjects Phase 1
Completed NCT03213288 - Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status N/A
Completed NCT00382564 - Magnetic Resonance Angiography to Diagnose Atherosclerotic Disease N/A
Recruiting NCT02979704 - A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia Phase 2/Phase 3
Completed NCT02569814 - A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin Phase 1
Completed NCT02428998 - Safety for 24 Weeks Intake of Korean Red Ginseng in Adults N/A
Completed NCT02280590 - Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia Phase 4
Completed NCT01678183 - Financial Incentives for Medication Adherence N/A
Completed NCT01694446 - Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose N/A
Completed NCT01426412 - A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol Phase 1
Completed NCT01131832 - Genetic Basis for Heterogeneity in Response of Plasma Lipids to Plant Sterols Phase 4
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Completed NCT00758303 - A Study to Evaluate the Lipid Regulating Effects of TRIA-662 Phase 2/Phase 3
Recruiting NCT00408824 - Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study) N/A
Terminated NCT00299169 - Randomized Trial Comparing N of 1 Trials to Standard Practice to Improve Adherence to Statins in Patients With Diabetes Phase 4
Completed NCT00362206 - Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin Phase 3
Completed NCT00381992 - Risk Assessment of Long-Haul Truck Drivers N/A
Completed NCT00414986 - Using Learning Teams for Reflective Adaptation for Diabetes and Depression N/A

External Links